• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Petco Love Announces Newest Board Members

    11/14/23 6:03:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email

    Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally

    SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide.

    Petco Love expands its Board of Directors, furthering its mission of leading change for pets including through adoption, as seen here at recent Petco Love Mega Adoption Event in Houston where 901 pets found homes.

    Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world for animals and the people who love them. In partnership with more than 4,000 animal welfare organizations and approximately 1,500 Petco pet care centers nationwide, Petco Love harnesses the power of love for impactful action to create a future in which no pet is unnecessarily euthanized.

    New independent Petco Love board members include:

    • Antoni Porowski joined the Petco Love Board in 2023. Antoni is a New York Times Bestselling author, host and executive producer of Netflix's Easy-Bake Battle culinary competition series and the upcoming No Taste Like Home from National Geographic and Studio Ramsay Global, and star of Netflix's award-winning hit Queer Eye. A self-taught cook, Antoni is a four-time Emmy nominee for his role as Queer Eye's resident food & wine expert. Antoni brings his lifelong passion for food to Yummers, his pet food brand cofounded alongside Queer Eye costar Jonathan Van Ness and pet industry veteran Rebecca Frechette Rudisch. In addition to Petco Love, Antoni serves on the board of the Equaversity Foundation which was established to organize international fundraising to support the LGBTQ+ community in his family's native Poland and is also a member of City Harvest's Food Council, a group of top chefs and culinary experts dedicated to spreading awareness and raising funds to end hunger in communities throughout New York City. "As an animal lover, it's truly an honour to take part in Petco Love's incredibly important work," said Porowski.



    • Ame Van Iden, serving as Board Secretary, is a strategic communications expert with more than 25 years of experience in high-level entertainment, media relations, brand and cause-related campaigns, and VIP/talent relations. As a results-driven publicist, she has created awareness for client and philanthropic endeavors. She worked alongside Christina Applegate to launch Right Action for Women, a nonprofit that helped women with breast cancer testing, and served on its board for nearly 20 years. In 2016, she founded VanIden Public Relations & Consulting. Prior to that, she served as the senior vice president of talent at PMK*BNC for 10 years, and as vice president at Wolf-Kasteler Public Relations for 16 years. "I am committed to helping animals," said Van Iden. "Using my experience to help Petco Love grow and succeed is my goal and great pleasure."



    • Dr. Ted Mashima is the chief strategy officer at the American Association of Veterinary Medical Colleges. Board-certified in both zoological and veterinary preventative medicine, his distinguished achievements include being president and executive director of the Asian & Pacific Islander American Scholarship Fund, as well as serving as the associate director for the Center for Public and Corporate Veterinary Medicine (Virginia Maryland College of Veterinary Medicine), director of development for the Barker Adoption Foundation, and as a consultant to the Geraldine R. Dodge Foundation. He was also the former VP and secretary at the American College of Zoological Medicine, and projects director for the National Association of Physicians for the Environment. "Petco Love's simple and beautiful mission is my mission too," said Mashima. "I desire to contribute, strongly, in whatever capacity my background and network can be most useful."



    • James Sloan, serving as Board Treasurer and Finance Committee Chair, brings over 15 years of private equity and corporate finance experience to further the mission of Petco Love. He is Head of Business Services, Direct Investments North America at GIC, a global institutional investor. In this role, James focuses on sourcing and executing private equity investments in Business Services and supporting and creating value for GIC's portfolio companies. Prior to GIC, James evaluated and executed private equity investments at CVC Capital Partners and Court Square Capital Partners in New York. He began his career in the M&A Group of Credit Suisse in New York and London. He currently serves on the boards of Veritext Legal Solutions and Lytx, Inc. He previously served on the boards of WWEX Group and Teneo and was a board observer of Petco Health & Wellness Company, Inc. "I am honored to join the Petco Love Board," said Sloan. "My lifelong passion and love for animals drive me to enthusiastically invest my energy and time to be a collaborative colleague and work hard to support all of Petco Love's initiatives."



    • Chris Sampson is currently the Head of Music Booking for Spotify. Prior to Spotify, Chris was the EVP of Programming at Superfly, a festival and events producer that is best known for co-creating Bonnaroo Music & Arts Festival and Outside Lands Music Festival. Chris also worked at Red Light Management as an artist manager at the beginning of his career. "I am honored to support Petco Love's mission by utilizing my professional experiences and relationships in the music industry to help pets in need," said Sampson.



    • Anna Skaya is the founder of Basepaws, a pet genetics company focused on early detection, prediction, and prevention of pet diseases. In 2017, Basepaws launched its first consumer DNA test for cats. The company subsequently expanded its offerings to include other cat-focused health tests and recently introduced dog DNA tests. Anna prides herself on promoting feline health and products far and wide, including during her appearances on Shark Tank, where she secured an investment. In 2022, Basepaws was acquired by Zoetis (NYSE:ZTS), the largest animal health company in the world, with Anna continuing to play a pivotal role in guiding Basepaws within the larger Zoetis organization, focusing on bringing the value of genetic testing to even more pet parents. Before her journey with Basepaws, Anna co-founded the UK-based MyCityDeal, which later became a part of Groupon. She then transitioned to lead Groupon Russia, where she had full P&L responsibilities. With many years of experience in the tech and consumer pet products sectors, Anna loves to bring her entrepreneurial way of being to everything she does. As a member of the Petco Love board, Anna's dedication to improving pet health and wellness remains at the forefront of her endeavors. "Beyond my professional qualifications, my deep personal commitment to improving the lives of pets, especially cats, is a driving force behind my interest in serving on the Petco Love Board," said Skaya.

    Other recent additions to the board include Petco leaders: Aaron Weiss (Senior Vice President of Vet Services; Petco Love Board Finance Committee), David Hallisey (SVP, Chief Communications Officer), and Whitney Miller (VP, Chief Veterinarian).

    Petco Love Board Chair Justin Tichy expressed his confidence about the collective energy the new board members bring, stating, "These additions mean Petco Love is in a powerful position to leverage far-reaching change and take advantage of new growth opportunities to further our mission. Our talented board members' expertise, experience, and perspective will help us make communities and pet families closer, stronger, and healthier."

    In addition to the newly added members, Petco Love board members include: Daymond John (CEO of FUBU and The Shark Group); Kevin Manion (Chief Financial Officer at Sunsweet Growers); Damien Harmon (Sr. Executive Vice President Customer, Channel and Enterprise Services, Best Buy); Tariq Hassan (Chief Marketing & CX Officer, McDonald's); and Susanne Kogut (President, Petco Love).

    Petco Love has built a one-of-a-kind ecosystem to serve pets and pet parents—and is armed with increasingly rich data and a more holistic understanding of what communities need and want. In addition to investing more than $370 million to date in adoption and other lifesaving efforts, and helping find loving homes for more than 6.7 million pets, Petco Love's latest direct-to-consumer initiatives include:

    • Petco Love Lost, a national lost and found pet database which is fast, free, and easy to use. Using innovative patented image-recognition technology, one photo can help reunite a lost pet with its family. Petco Love Lost partners with over 2,500 animal shelters nationwide and can be used by anyone who loses or finds a pet.



    • Vaccinated and Loved, started in 2021, an initiative to end life-threatening pet diseases by allocating one million free pet vaccines to community-owned pets and committing to another one million vaccines in 2022. This program was created to increase the number of pets vaccinated for distemper, parvovirus, and panleukopenia, as well as decrease the spread of disease should these pets enter shelters.

    To learn more about Petco Love's lifesaving work, visit petcolove.org or follow along on Facebook, Instagram, X, and Threads.

    About Petco Love

    Petco Love is a life-changing nonprofit organization that makes communities and pet families closer, stronger, and healthier. Since our founding in 1999 as the Petco Foundation, we've empowered animal welfare organizations by investing $370 million in adoption and other lifesaving efforts. We've helped find loving homes for more than 6.7 million pets in partnership with Petco and organizations nationwide. Our love for pets drives us to lead with innovation, creating tools animal lovers need to reunite lost pets, and lead with passion, inspiring and mobilizing communities and our more than 4,000 animal welfare partners to drive lifesaving change alongside us. Is love calling you? Join us. Visit petcolove.org or follow us on Facebook, Instagram, X, Threads, and LinkedIn to be part of the lifesaving work we lead every day.

    Contact: Crystal Bugary, Petco Love, [email protected]

     

    (PRNewsfoto/Petco Love)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/petco-love-announces-newest-board-members-301986968.html

    SOURCE Petco Love

    Get the next $ZTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    9/6/2023$230.00Buy
    HSBC Securities
    7/12/2022$205.00Overweight
    Piper Sandler
    3/9/2022$232.00 → $208.00Neutral
    Citigroup
    More analyst ratings

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zoetis Announces First Quarter 2025 Results

      Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates Full Year 2025 Revenue Guidance to $9.425 - $9.575 Billion to Reflect the Impact of Foreign Exchange and Maintains Guidance for Organic Operational Revenue Growth of 6% to 8% Updates Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income t

      5/6/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nu

      3/27/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Participate in Upcoming Investor Conferences

      Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. Bank of America Securities 2025 Animal Health Summit on Thursday, February 27, 2025 at 1:20 p.m. ET. Barclays Global Healthcare Conference on Tuesday, March 11, 2025 at 10:30 a.m. ET. Investors and other interested parties can access live audio webcasts of the presentations by visiting http://investor.zoetis.com/events-presentations. Replays will also be available on the Zoetis website at the conclusion of each event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind b

      2/20/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

      For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

      1/13/22 10:26:13 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ZTS
    SEC Filings

    See more

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ZTS
    Financials

    Live finance-specific insights

    See more
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/13/24 5:17:36 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      1/26/24 11:49:41 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/9/23 11:37:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Zoetis with a new price target

      Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

      12/2/24 7:04:18 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Zoetis with a new price target

      BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00

      7/25/24 6:48:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Zoetis with a new price target

      Stifel reiterated coverage of Zoetis with a rating of Buy and set a new price target of $215.00 from $195.00 previously

      1/12/24 8:18:04 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Zoetis Inc.

      10-Q - Zoetis Inc. (0001555280) (Filer)

      5/6/25 1:29:54 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Zoetis Inc. (0001555280) (Filer)

      5/6/25 7:03:35 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zoetis Inc.

      DEFA14A - Zoetis Inc. (0001555280) (Filer)

      4/9/25 9:04:50 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Vice President Polzer Robert J

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:24 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Vice President Sarbaugh Keith

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:13 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Vice President Fuller Julie

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:03 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Announces First Quarter 2025 Results

      Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates Full Year 2025 Revenue Guidance to $9.425 - $9.575 Billion to Reflect the Impact of Foreign Exchange and Maintains Guidance for Organic Operational Revenue Growth of 6% to 8% Updates Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income t

      5/6/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nu

      3/27/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Reports Fourth Quarter and Full Year 2024 Results

      Reports Revenue of $2.3 Billion, Growing 5%, and Net Income of $581 Million, or $1.29 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis for Fourth Quarter 2024 Delivers 6% Operational Growth in Revenue and 9% Operational Growth in Adjusted Net Income for Fourth Quarter 2024 Delivers 9% Organic Operational Growth in Revenue for Fourth Quarter 2024 After Accounting for the Divestiture of the Medicated Feed Additive Product Portfolio, Certain Water Soluble Products and Related Assets Reports Adjusted Net Income of $632 Million, or Adjusted Diluted EPS of $1.40, for Fourth Quarter 2024 Reports Revenue of $9.3 Billion, Growing 8%, and Net Income of $2.5

      2/13/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

      New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu

      11/11/24 9:20:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

      Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand

      4/1/24 4:30:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Petco Love Announces Newest Board Members

      Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide. Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world

      11/14/23 6:03:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care